REG - Belluscura PLC - Total Voting Rights

BelluscuraAnnouncement

28/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240328:nRSb3462Ia&default-theme=true

RNS Number : 3462I  Belluscura PLC  28 March 2024

28 March 2024

 

Belluscura plc

("Belluscura" or the "Company")

 

Total Voting Rights

 

Belluscura plc (AIM: BELL), a leading medical device developer focused on
lightweight and portable oxygen enrichment technology, announces that the
total number of Ordinary Shares in the capital of the Company in issue is
164,385,117 with each Ordinary Share carrying the right to one vote. There are
no Ordinary Shares held in treasury and therefore the total number of voting
rights in the Company is 164,385,117. The above figure may be used by
Shareholders in the Company as the denominator for the calculations by which
they will determine if they are required to notify their interest in, or a
change to their interest in, the share capital of the Company under the FCA's
Disclosure Guidance and Transparency Rules.

 

 

 

Enquiries:

For further information, please contact:

 

 Belluscura plc                            www.belluscura.com
 Robert Rauker, Chief Executive Officer    via MHP
 Simon Neicheril, Chief Financial Officer

 SPARK Advisory Partners Limited           Tel: +44 (0)20 3368 3550

(NOMAD)
 Neil Baldwin / Jade Bayat

 Dowgate Capital Limited                   Tel: +44 (0)20 3903 7715

(Broker)
 James Serjeant / Russell Cook /

Nicholas Chambers

 MHP Communications                        Tel: +44 (0)20 3128 8100 / +44 7884 494112

(Financial PR and Investor Relations)    Email: belluscura@mhpgroup.com
 Katie Hunt / Matthew Taylor

 

 

About Belluscura plc (www.belluscura.com (https://belluscura.com/) )

Belluscura is a UK medical device company focused on developing high
performing, lightweight and portable oxygen enrichment technology used in a
broad range of industries and therapies. Our innovative oxygen technologies
are designed with a global purpose: to create improved health, mobility and
economic outcomes for patients, healthcare providers and insurance
organisations.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRSEEFFMELSEFD